RxDoctor Payments Data

Willis Chang, MD

Infectious Disease · Waipahu, HINPI 1558306720

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.0% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 57.9% of the total. 2025 is the largest year on record at $1,276, 2.1 times the $600 reported in 2019.

$4,404in general payments, 2019–2025

Across 172 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Insmed, Inc.$696
  • Abiomed$295
  • Gilead$244
  • Pfizer$154
  • Cumberland Pharmaceuticals, Inc.$148
  • plus $318 from 6 others

What the payments were for

  • Consulting fees$1002%
  • Food & beverage$4,22896%
  • Education$772%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)111$2,550
Insmed, Inc.30$696
Abiomed8$295
Gilead2$244
Pfizer8$154
Cumberland Pharmaceuticals, Inc.2$148
Johnson & Johnson5$117
Comsort, Inc1$100
E.r. Squibb & Sons, L.L.C.2$43
Indivior Inc.1$25
Philips North America LLC1$17
Merck1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,404 in reported general payments places this provider in the 80th percentile of 28 infectious disease providers in Hawaii.

See all infectious disease providers in Hawaii

Medicare billing

Part B allowed, 2024
$27,458
Medicare patients
50
Services billed
301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala41$182,494
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$46,872
JulucaDolutegravir/Rilpivirine11$37,091
Darunavir22$25,125
Rifabutin12$6,611
Ritonavir27$4,108
Moxifloxacin Hcl11$1,942
Ethambutol Hcl26$1,537
Azithromycin14$13

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$244$229,36653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 28 infectious disease providers in Hawaii.

Other infectious disease in Waipahu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →